← Back to all trials
Completed
NCT05683951
Clinical Trial to Evaluate the Efficacy and Safety of DWKH
Conditions: Respiratory Infection
Sex: All
Ages: 19 Years – 80 Years
Phase: PHASE3
Enrollment: 186
Sponsor: Daewon Pharmaceutical Co., Ltd.
Location: Korea, Republic of
Summary
Randomized, Double-blind, Parellel, Multicenter, Active-controlled
Eligibility Criteria
Inclusion Criteria:Male and female aged between 19 and 80.Patients whose BSS score is over 5.Exclusion Criteria:Patients allergic to any ingredients of the study drugs.Moderate liver disease (ALT or AST > UNLx3).Moderate lung disease.Uncontrolled HTN.Uncontrolled DM.Uncontrolled thyroidism.Patients who is needed antibiotics during the study period.In the case of women, pregnant(Urine-HCG positive) or lactating women.
Source: ClinicalTrials.gov (NCT05683951). StuddyBuddy aggregates publicly available trial information.
